Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted...
Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
About this item
Full title
Author / Creator
Publisher
Egypt: Hindawi Publishing Corporation
Journal title
Language
English
Formats
Publication information
Publisher
Egypt: Hindawi Publishing Corporation
More information
Scope and Contents
Contents
The treatment strategy in multiple myeloma (MM) is to get complete remission followed by high-dose chemotherapy and autologous Hematopoietic Stem Cell Transplantation (HSCT). Neoplastic Plasma Cells (NPCs) are CD45-/dim, CD38+high, CD138+, CD19−, and CD56+high in most cases. The description of this immunophenotype is of major importance as it lead...
Alternative Titles
Full title
Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3705753
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3705753
Other Identifiers
ISSN
2090-441X,2090-4428
E-ISSN
2090-4428
DOI
10.1155/2013/847672
